Bradley Rankin, MD
Allergy & Immunology · Paducah, KYNPI 1457355893
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,000 of the $27,755 with a category attached, or 79.3%. AstraZeneca accounts for 73.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $16,463 and has fallen 95.6% since, to $727 in 2024.
Across 269 payments — averaging $103.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- Amgen$4K
- GSK$797
- Regeneron Healthcare Solutions, Inc.$571
- Sanofi$446
- Pfizer$269
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$22,00079%
- Travel & lodging$2471%
- Food & beverage$5,49220%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $20,357 |
| Amgen | 14 | $3,903 |
| GSK | 46 | $797 |
| Regeneron Healthcare Solutions, Inc. | 21 | $571 |
| Sanofi | 21 | $446 |
| Pfizer | 17 | $269 |
| Kaleo, Inc. | 14 | $240 |
| CSL Behring | 9 | $217 |
| Merck | 2 | $169 |
| Boehringer Ingelheim | 8 | $145 |
| Genentech USA, Inc. | 7 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $113 |
| Incyte Corporation | 3 | $57 |
| Novartis | 3 | $56 |
| Pharming Healthcare, Inc. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Octapharma USA, Inc. | 2 | $40 |
| Optinose US, Inc. | 2 | $39 |
| Shire North American Group Inc | 2 | $32 |
| Biocryst US Sales Co., LLC | 1 | $29 |
| LEO Pharma Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $14 |
| Grifols USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,755 in reported general payments places this provider in the 75th percentile of 66 allergy & immunology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $28,780 |
| Spiriva RespimatTiotropium Bromide | 37 | $22,536 |
| SymbicortBudesonide/Formoterol Fumarate | 63 | $18,248 |
| DuleraMometasone/Formoterol | 28 | $10,705 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $9,479 |
| Epinephrine | 39 | $9,015 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,965 |
| BreynaBudesonide/Formoterol Fumarate | 24 | $4,502 |
| Azelastine Hcl | 168 | $3,996 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 16 | $3,926 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $3,528 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,309 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $2,231 |
| Montelukast Sodium | 235 | $1,856 |
| Mometasone Furoate | 17 | $1,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $797 | $38,25963 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $145 | $29,50051 claims |
| AstraZenecaSymbicort | $20,357 | $18,24863 claims |
| MerckDulera | $169 | $10,70528 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $9,01539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 66 allergy & immunology providers in Kentucky.
Other allergy & immunology in Paducah
- Julie DavenportPaducah$7K
- Lee CloreOwensboro$841K
- James SublettLouisville$588K
- Hans OttoFlorence$381K
- Stephen PollardLouisville$301K
- Douglas LotzLouisville$199K
- James SublettLouisville$194K
- Timothy FranxmanLouisville$162K
- Jeremy JonesLouisville$149K
- Rajiv AroraLexington$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.